Tadalafil tablets recalled due to manufacturing process deviations
Accord Healthcare is recalling Tadalafil 2.5 mg tablets following discovery of manufacturing deviations during an FDA inspection. Approximately 36,773 bottles were distributed in the United States, Puerto Rico, and Canada.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving manufacturing process deviations with no reported illnesses or injuries. Per the severity rubric, Class II recalls without hospitalization reports and with theoretical hazards score 2 (Moderate).
Plain-English summary
Accord Healthcare, Inc. is recalling Tadalafil Tablets, USP, 2.5 mg due to manufacturing deviations discovered during an FDA inspection. The affected medication is supplied in 30-count and 500-count bottles with varying batch codes. Approximately 36,773 bottles have been distributed across the United States, including Puerto Rico, and Canada.
The recall was initiated following identification of Current Good Manufacturing Practice (CGMP) deviations. The specific nature of these deviations is not detailed in the recall notice.
Consumers with this medication should contact their healthcare provider or pharmacist for guidance. For specific product information including affected batch numbers and NDC codes, consumers may contact the FDA or Accord Healthcare.
The recalled product
- Product
- TADALAFIL (TADALAFIL)
- Brand
- TADALAFIL
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Oral tablet
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (16)
- Batches: a) P2002522
- Exp. Date 4/30/2023
- P2005817
- P2005816
- Exp. Date 10/31/2023
- P2203687
- Exp. Date 6/30/2025
- b) P2002521
- P2005818
- P2100075
- Exp. Date 12/31/2023
- P2100996
- P2100997
- P2100998
- P2100999
- Exp. Date 1/31/2024
UPCs (5)
- 0316729372107
- 0316729369107
- 0316729370103
- 316729369107
- 316729369169
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · TADALAFIL
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Tadalafil tablets recalled for manufacturing process deviations
FDA (Drugs) · 2023-04-12
- HighTadalafil tablets recalled for manufacturing quality control deviations
FDA (Drugs) · 2023-03-08
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27